Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Outline of Final Research Achievements |
We previously demonstrated that hematopoietic stem cell (HSC)-like cells were obtained from mouse induced pluripotent stem cells (iPSCs). When mouse iPSCs are differentiated into hemogenic endothelial cells (HECs) and a transcription factor Lhx2, known to induce ex vivo amplification of adult HSCs, is introduced, HSC-like cells are differentiated. Based on this finding, we challenged to induced HSCs from human iPSCs. First, we established an efficient in vitro hematopoietic differentiation induction system from human iPSCs. We found that a GSK3beta inhibitor greatly improved hematopoietic differentiation from human iPSCs. Using this method, we carried out enforced expression of Lhx2 into human iPSC-derived HECs. However, HSC-like cells were hardly obtained.
|